OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr Gupta on the MAIN-CAV Trial of Maintenance Cabozantinib Plus Avelumab in mUC

June 27th 2023

Shilpa Gupta, MD, discusses the design, methodology, and potential significance of the ongoing phase 3 MAIN-CAV trial in patients with locally advanced/metastatic urothelial carcinoma

Dr. Barata sobre el Ensayo EMBARK en Pacientes con Cáncer de Próstata no Metastásico de alto Riesgo y Sensible a Hormonas.

June 26th 2023

Pedro Barata, MD, MSc, discusses the importance of the phase 3 EMBARK trial in patients with high-risk, nonmetastatic hormone-sensitive prostate cancer.

Dr. Barata sobre las Necesidades no Cubiertas de los Pacientes con Cáncer de Próstata

June 26th 2023

Pedro Barata, MD, MSc, discusses remaining unmet needs for patients with prostate cancer.

Dr Monga on the Investigation of PRT811 in High-Grade Glioma or Uveal Melanoma

June 26th 2023

Varun Monga, MD, discusses the investigation of the protein arginine methyltransferase 5 brain-penetrant inhibitor PRT811 in patients with recurrent high-grade glioma or uveal melanoma.

Dr Komrokji on the Classification of Patients With Myelodysplastic Syndromes

June 26th 2023

Rami Komrokji, MD, discusses key findings from an expanded analysis of the classification of patients with myelodysplastic syndromes.

Dr Montesinos on Quizartinib Plus Chemotherapy in Newly Diagnosed FLT3-ITD Wild-Type AML

June 26th 2023

Pau Montesinos, MD, PhD, discusses preliminary efficacy seen with the addition of quizartinib to standard 7+3 chemotherapy in patients with newly diagnosed FLT3-ITD wild-type acute myeloid leukemia.

Dr Oselin on a Subgroup Analysis of the PEARLS/KEYNOTE-091 Trial in NSCLC

June 26th 2023

Kersti Oselin, MD, PhD, discusses a subgroup analysis from the phase 3 PEARLS/KEYNOTE-091 study of pembrolizumab in patients with early-stage non‒small-cell lung cancer following resection.

Dr Coupe on the Investigation of IMM60 Plus Pembrolizumab in Advanced Melanoma and NSCLC

June 26th 2023

Nicholas Coupe, MBBS, PhD, discusses the investigation of IMM60 plus pembrolizumab in patients with advanced melanoma or metastatic non-small cell lung cancer.

Combinación de Ribociclib y Terapia Endocrina en Pacientes con Cáncer de Mama Temprano, Positivo a Receptores Hormonales y Negativo a HER2

June 26th 2023

Francisco Javier Esteva, MD, PhD, discusses key findings from the phase 3 NATALEE trial in patients with hormone receptor–positive, HER2-negative early breast cancer.

Dr Wermke on the Investigation of BI 764532 in DLL3+ SCLC and NEC

June 23rd 2023

Martin Wermke, MD, discusses the investigation of BI 764532 in patients with DLL3-positive small cell lung cancer and neuroendocrine carcinoma.

Dr O'Reilly on Survival Outcomes of the NAPOLI 3 trial in Metastatic PDAC

June 23rd 2023

Eileen M. O'Reilly, MD, discusses survival outcomes from the phase 3 NAPOLI 3 trial in patients with metastatic pancreatic ductal adenocarcinoma.

Dr Munshi on the Future of CAR T-Cell Therapy in Multiple Myeloma

June 23rd 2023

Nikhil C. Munshi, MD, discusses potential future directions for ciltacabtagene autoleucel and other CAR T-cell therapies in patients with multiple myeloma.

Dr Hamilton on the Investigation of HER3-DXd in ER+ Breast Cancer and TNBC

June 23rd 2023

Erika P. Hamilton, MD, discusses the investigation of patritumab deruxtecan in heavily pretreated patients with metastatic estrogen receptor-positive or triple-negative breast cancer with varying levels of HER3 expression in a phase 2 trial.

Dr Marouf on the Efficacy of PD-L1 Inhibition in R/R Extranodal NK/T-cell Lymphoma

June 23rd 2023

Amira Marouf, MD, PhD student, discusses the efficacy of PD-L1 inhibitors in relapsed/refractory extranodal natural killer/T-cell lymphoma.

Dr Mascarenhas on the Initial Efficacy of Navtemadlin Plus Ruxolitinib in Myelofibrosis

June 23rd 2023

John Mascarenhas, MD, discusses initial clinical activity observed with the addition of the first-in-class MDM2 inhibitor navtemadlin to ruxolitinib in primary or secondary myelofibrosis.

Dr Miron on the Characteristics of Intraductal Carcinoma of the Prostate

June 23rd 2023

Benjamin Miron, MD, discusses the rationale for investigating molecular alterations in patients with intraductal carcinoma of the prostate.

Dr Raghav on the Rationale Behind DESTINY-CRC02 in HER2+ mCRC

June 23rd 2023

Kanwal P. S. Raghav, MBBS, MD, discusses the rationale behind the phase 2 DESTINY-CRC02 trial evaluating fam-trastuzumab deruxtecan-nxki in patients with metastatic colorectal cancer (mCRC) with HER2 amplification or overexpression.

Dr Vaishampayan on the Impact of TKI Combination Therapies in the Treatment of RCC

June 23rd 2023

Ulka Nitin Vaishampayan, MBBS, discusses updated data for frontline TKI combination therapies in the treatment of patients with metastatic renal cell carcinoma.

Dr Yu on the Investigation of BL-B01D1 in Lung Cancer

June 22nd 2023

Helena A. Yu, MD, discusses findings from a phase 1 trial investigating the bispecific antibody-drug conjugate BL-B01D1, which is directed against both HER3 and EGFR, in patients with locally advanced or metastatic solid tumors such as non–small cell lung cancer and small cell lung cancer.

Dr Pistilli on Understanding Dynamic HER2 Expression in Metastatic Breast Cancer

June 22nd 2023

Barbara Pistilli, MD, discusses the importance of understanding how HER2 expression can change over time when assessing target expression in metastatic breast cancer.